title: Proinflammatory cytokines downregulate gene expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery endothelial cells.
abstract: We evaluated the effects of cytokines on the catalytic activity and expression of porcine pulmonary artery endothelial cell (PAEC) constitutive (eNOS) and inducible (iNOS) isoforms of nitric oxide synthase (NOS). Exposure of PAEC to the combination of IFN-gamma, TNF-alpha, and IL-1 beta did not alter iNOS activity in cytosolic and membrane fractions but significantly (p < 0.01) reduced eNOS activity in the membrane fraction, but not in the cytosolic fraction, after a 24-h exposure. The cytokine-induced loss of membrane fraction eNOS activity was associated with significant reductions of eNOS mRNA and protein content (p < 0.01 for both). Treatment with the protein synthesis inhibitor, cycloheximide, but not the transcriptional inhibitor actinomycin D prevented cytokine-induced reduction of eNOS mRNA expression. These results suggest that cytokine-induced loss of catalytic activity of eNOS is associated with a reduction in eNOS mRNA and protein mass and that cytokines alter eNOS mRNA stability. Inhibition of protein synthesis prevented reduction of eNOS mRNA by cytokines, suggesting that the mechanism by which cytokines alter eNOS mRNA stability involves protein synthesis.
authors.affiliation: Department of Medicine, University of Florida, Gainesville 32608-1197, USA.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: J M
authors.initials: JM
authors.lastname: Patel
authors.forename: Y D
authors.initials: YD
authors.lastname: Li
authors.forename: E R
authors.initials: ER
authors.lastname: Block
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015152:Blotting, Northern; D015153:Blotting, Western; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D016207:Cytokines / Q000494:pharmacology*; D003609:Dactinomycin / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects* / Q000502:physiology; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects* / Q000502:physiology; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D007536:Isomerism; D019001:Nitric Oxide Synthase / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D011651:Pulmonary Artery / Q000166:cytology / Q000201:enzymology; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D013552:Swine; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D004338:Drug Combinations; D007375:Interleukin-1; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D003609:Dactinomycin; D007371:Interferon-gamma; D003513:Cycloheximide; D019001:Nitric Oxide Synthase